A comprehensive view of Landos Biopharma Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
AbbVie to acquire Landos Biopharma for an estimated US$212.5M; deal includes NX-13, a potentially ground-breaking oral treatment for conditions such as ulcerative colitis and Crohn's disease
Published:
March 25, 2024
by AbbVie Inc.
|
Ask us about our Health Care Sector market view